Evidence map›Paper›PMID 40452181›Full record

ArticleOncoimmunology2025

The combination of body mass index and serum creatinine levels predicts survival in patients with Hodgkin lymphoma treated with nivolumab in the CheckMate 205 study.

Rosaria De Filippi, Fortunato Morabito, Giovanni Tripepi, Stephen M Ansell, Sara Mele, Emanuela Morelli, Domenico Mallardo, Daniela Donnarumma, Francesco Volzone, Alev Akyol and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Rosaria De FilippiDipartimento di Medicina Clinica e Chirurgica, Università degli Studi Federico II, Naples, Italy.ORCID 0000-0001-7899-3071
Fortunato MorabitoEmatologia Oncologica e Trapianto di Cellule Staminali, Istituto Nazionale Tumori-IRCCS-Fondazione 'G. Pascale', Naples, Italy.
Giovanni TripepiConsiglio Nazionale delle Ricerche, Istituto di Fisiologia Clinica del Consiglio Nazionale delle Ricerche (CNR), Reggio, Calabria, Italy.
Stephen M AnsellDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Sara MeleEmatologia Oncologica e Trapianto di Cellule Staminali, Istituto Nazionale Tumori-IRCCS-Fondazione 'G. Pascale', Naples, Italy.
Emanuela MorelliEmatologia Oncologica e Trapianto di Cellule Staminali, Istituto Nazionale Tumori-IRCCS-Fondazione 'G. Pascale', Naples, Italy.
Domenico MallardoDipartimento Melanoma, Immunologia Oncologica Sperimentale e Terapie Innovative, Istituto Nazionale Tumori-IRCCS-Fondazione 'G. Pascale', Naples, Italy.
Daniela DonnarummaEmatologia Oncologica e Trapianto di Cellule Staminali, Istituto Nazionale Tumori-IRCCS-Fondazione 'G. Pascale', Naples, Italy.
Francesco VolzoneEmatologia Oncologica e Trapianto di Cellule Staminali, Istituto Nazionale Tumori-IRCCS-Fondazione 'G. Pascale', Naples, Italy.
Alev AkyolBristol Myers Squibb, Princeton, NJ, USA.
Annarosa CuccaroEmatologia Oncologica e Trapianto di Cellule Staminali, Istituto Nazionale Tumori-IRCCS-Fondazione 'G. Pascale', Naples, Italy.
Mariangela SaggeseEmatologia Oncologica e Trapianto di Cellule Staminali, Istituto Nazionale Tumori-IRCCS-Fondazione 'G. Pascale', Naples, Italy.
Matteo BonanniEmatologia Oncologica e Trapianto di Cellule Staminali, Istituto Nazionale Tumori-IRCCS-Fondazione 'G. Pascale', Naples, Italy.
Maria EspositoEmatologia Oncologica e Trapianto di Cellule Staminali, Istituto Nazionale Tumori-IRCCS-Fondazione 'G. Pascale', Naples, Italy.
Stefania CrisciEmatologia Oncologica e Trapianto di Cellule Staminali, Istituto Nazionale Tumori-IRCCS-Fondazione 'G. Pascale', Naples, Italy.
Pier Luigi ZinzaniIRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli" and Università di Bologna, Bologna, Italy.
Antonio PintoEmatologia Oncologica e Trapianto di Cellule Staminali, Istituto Nazionale Tumori-IRCCS-Fondazione 'G. Pascale', Naples, Italy.ORCID 0000-0002-9425-9026

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with solid tumors and a higher body mass index (BMI) experience improved survival after receiving anti-PD1 antibodies. The predictive role of BMI in Hodgkin Lymphoma (HL), the most sensitive malignancy to PD1-blockade, remains unclear. We analyzed the association between BMI and survival outcomes in patients treated with the anti-PD-1 antibody nivolumab within the CheckMate 205 study. Patients with a lower BMI (<24.03 kg/m

Indexed as

Antineoplastic Agents, ImmunologicalBody Mass IndexCreatinineHodgkin DiseaseNivolumabAdultAgedFemaleHumansMaleMiddle AgedPrognosisYoung AdultAntineoplastic Agents, ImmunologicalCreatinineNivolumabBody Mass indexHodgkin LymphomaPD1-blockade

Identifiers

PMID40452181
PMCPMC12952732

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.